A5040116413- Dementia and Cognitive Impairment Research
- Parkinson's Disease Mechanisms and Treatments
- Epigenetics and DNA Methylation
- Neurobiology of Language and Bilingualism
- Posttraumatic Stress Disorder Research
- Nuclear Receptors and Signaling
- Bioinformatics and Genomic Networks
- Voice and Speech Disorders
- Migration, Health and Trauma
- Intergenerational Family Dynamics and Caregiving
- Evolutionary Psychology and Human Behavior
- RNA Research and Splicing
- Neurological disorders and treatments
- Neuroendocrine regulation and behavior
- Kruppel-like factors research
- Resilience and Mental Health
- Chronic Disease Management Strategies
- Anesthesia and Neurotoxicity Research
- MicroRNA in disease regulation
- Alzheimer's disease research and treatments
- Attachment and Relationship Dynamics
- Stress Responses and Cortisol
- Metabolomics and Mass Spectrometry Studies
- Autism Spectrum Disorder Research
- Neurogenesis and neuroplasticity mechanisms
Maastricht University
2022-2025
Maastricht University Medical Centre
2022-2023
European Graduate School of Neuroscience
2022-2023
Cognitive impairment is a debilitating symptom in Parkinson's disease (PD). We aimed to establish an accurate multivariate machine learning (ML) model predict cognitive outcome newly diagnosed PD cases from the Progression Markers Initiative (PPMI). Annual assessments over 8-year time span were used define two outcomes of (i) impairment, and (ii) dementia conversion. Selected baseline variables organized into three subsets clinical, biofluid genetic/epigenetic measures tested using four...
The established link between DNA methylation and pathophysiology of dementia, along with its potential role as a molecular mediator lifestyle environmental influences, positions blood-derived promising tool for early dementia risk detection.
Growing evidence suggests that clinical, pathological, and genetic heterogeneity in late-onset Alzheimer′s disease contributes to variable therapeutic outcomes, potentially explaining many trial failures. Advances molecular subtyping through proteomic transcriptomic profiling reveal distinct patient subgroups, highlighting complexity beyond amyloid-beta plaques tau tangles. This insight underscores the need expand across new layers, identify novel drug targets for different subgroups. In...
In the progressive phase of multiple sclerosis (MS), hampered differentiation capacity oligodendrocyte precursor cells (OPCs) eventually results in remyelination failure. We have previously shown that DNA methylation Id2/Id4 is highly involved OPC and remyelination. this study, we took an unbiased approach by determining genome-wide patterns within chronically demyelinated MS lesions investigated how certain epigenetic signatures relate to capacity. compared transcriptional profiles between...
Abstract Introduction In the progressive phase of multiple sclerosis (MS), hampered differentiation capacity oligodendrocyte precursor cells (OPCs) eventually results in remyelination failure. We have previously shown that DNA methylation Id2/Id4 is highly involved OPC and remyelination. this study, we took an unbiased approach by determining genome-wide patterns within chronically demyelinated MS lesions investigated how certain epigenetic signatures relate to capacity. Methods compared...
Abstract Background Cognitive impairment is a debilitating symptom in Parkinson’s disease (PD), with high variability onset and course of progression. This present study aimed to establish an accurate multivariate machine learning model predict cognitive outcome newly diagnosed PD. Method Using baseline measures from the Progression Markers Initiative (PPMI) cohort we subset clinical, biofluid genetic/epigenetic variables. Annual assessments over eight‐year time span were used define two...
Abstract Recent studies have highlighted the role of oxytocin (OXT) in Alzheimer’s disease (AD) dementia and demonstrated its potential as a therapeutic target to reverse cognitive impairment mitigate AD pathology. Epigenetic dysregulation OXT has been identified brain tissue from patients, DNA methylation levels exact same locus blood healthy aged individuals shown predictive biomarker value for conversion AD. Building on these insights, we investigated status promoter prospective cohort...
ABSTRACT INTRODUCTION Given the established association between DNA methylation and pathophysiology of dementia its plausible role as a molecular mediator lifestyle environment, blood-derived data could enable early detection risk. METHODS In conjunction with an extensive array machine learning techniques, we employed whole blood genome-wide surrogate for 14 modifiable non-modifiable factors in assessment risk two independent cohorts Alzheimer’s disease (AD) Parkinson’s (PD). RESULTS We...
Abstract Cognitive impairment is a debilitating symptom in Parkinson’s disease (PD). We aimed to establish an accurate multivariate machine learning (ML) model predict cognitive outcome newly diagnosed PD cases from the Progression Markers Initiative (PPMI). Annual assessments over eight-year time span were used define two outcomes of i) impairment, and ii) dementia conversion. Selected baseline variables organized into three subsets clinical, biofluid genetic/epigenetic measures tested...
<p class="first" dir="auto" id="d24248855e162">In Europe about 1% of people over the age 60 are diagnosed with Parkinson’s disease (PD) a tendency to increase, representing major socioeconomic challenge ( <i>1, 2</i>). PD is characterized by impaired movement control and progressively degenerating neurons in substantia nigra brain. As result, amount dopamine corpus striatum lowered. <sup> </sup>Treatment options mainly center around substituting dopamine, principle introduced 1960’s. Since...
Abstract Background Cognitive impairment is the first manifestation of dementia. However, rate changes in cognitive function varies between individuals and unraveling heterogeneity trajectory decline dementia crucial for adopting a suitable treatment. In this study, first, we aimed at identifying distinct trajectories function, next used extensive machine learning approaches on multi‐trait ploygenic scores,CSF proteomics, plasma lipidomics metabolomics data classification identified initial...
Abstract Background Accumulating evidence shows that the heterogeneity and temporal complexity of Alzheimer’s Disease contribute to treatment failure. Advances in omics technologies along with development efficient integrative analytical pipelines, provide a unique opportunity investigate drivers at multiple molecular levels. Method We used genome‐wide DNA methylation data generated postmortem prefrontal cortex samples from two independent biobanks Brain for Dementia Research (BDR; n = 382)...
Abstract Cognitive impairment is a debilitating symptom in Parkinson’s disease (PD). We aimed to establish an accurate multivariate machine learning (ML) model predict cognitive outcome newly diagnosed PD cases from the Progression Markers Initiative (PPMI). Annual assessments over eight-year time span were used define two outcomes of i) impairment, and ii) dementia conversion. Selected baseline variables organized into three subsets clinical, biofluid genetic/epigenetic measures tested...
Abstract Background Cognitive impairment is a common and debilitating symptom in Parkinson’s disease (PD) with high variability individual trajectory of decline. We sought to explore heterogeneity the cognitive change cohort early stage PD patients test association cumulative genetic risk identified large scale Genome Wide Association Studies (GWAS). Method Using longitudinal measures Montreal Assessment (MoCA) we employed latent class mixed modelling (LCMM) identify investigate unknown...